Alex Trapp

Biotechnologist @RetroBio_

[Alex Trapp @AlexandreTrapp]

Last week, on the cover of @NatureAging, we published the first computational framework for epigenetic age estimation at single-cell resolution.

A fantastic collaboration with @CsabaKerepesi and @VadimGladyshev in the @gladyshev_lab @harvardmed!

https://t.co/2QXfmVqXh4

1/🧵

[Jake Wintermute 🧬/acc @SynBio1]

I also can't find a way to use my genome. But whatever it was fun to vibe code my ancestry analysis (turns out I'm white) my disease risk scores (normal) and my IQ (normal)

I recommend it. But don't pay $7902. Surf on over to @TheODINInc and get yourself a genome for $599

[The ODIN @TheODINInc]

the odin is dead. long live the open discovery institute.

new name. new site. new logo. new kits. same goal: make biotechnology something you can actually do.

https://t.co/5G0lVzIeXM

[Matt Buckley @MatttBuckley]

Embryo selection.

But, for we the living, brain cell replacement is an ambitious path worth developing further.

[José Luis Ricón Fernández de la Puente @ArtirKel]

We started a new program at @RetroBio_ to explore what can be achieved by going deep on combinations of small molecules to achieve rejuvenation. Incepted by me and led by @z_chiang

[Best Movie Moments 🍿 @BestMovieMom]

Hans Zimmer performing the main theme from “Man of Steel” live in concert. Goosebumps.

[Aging Science News @AgingBiology]

Sustained epigenetic rejuvenation of serially engrafting human iPSC-derived HSCs
https://t.co/d4sH91wgKh

[zack chiang @z_chiang]

was initially quite skeptical of "industry PhDs" but Arjun is one of the most prolific scientists I've worked with

many people assume that iPSC therapies are just for replacing lost cells, but here we show we can rejuvenate the system that forms ~80% of human cells!

[Arjun Jain @arjunjain527]

I’m excited to share the first paper from my PhD research at @RetroBio_ (and my first paper as first author) - now on bioRxiv!

Can we take adult human cells, turn them into blood-forming stem cells, and build a new blood system that is both functional and molecularly young?

Our preprint: https://t.co/1Z1w0l3Kag

[Matt Buckley @MatttBuckley]

Sustained molecular rejuvenation demonstrated in serially transplanted iHSCs (stem-cell-derived blood generating cells) -- a new preprint from @RetroBio_

[Rob Kalesnik-Orszulak @roborszulak]

I'm hiring a CMC Regulatory Lead to drive CMC Regulatory strategy and execution at Retro. This is an opportunity to join a fast-rising, early-stage biotech backed by Sam Altman that is developing therapeutics that target the fundamental drivers of aging to treat and prevent multiple downstream age-related diseases.

Our pipeline is unusually broad for a company at our stage: cell and gene therapies, small molecules, and AI-designed protein therapeutics. For someone who loves the craft of CMC regulatory work, this is a chance to work at real technical depth across multiple therapeutic modalities and help build something important.

https://t.co/FblQoAOZqZ

[Rob Kalesnik-Orszulak @roborszulak]

really enjoyed being a part of this conversation - with therapies now starting to target the upstream cause (aging) of multiple downstream serious diseases, there is so much opportunity for us to unlock over the next decade

some things worth considering:

non-legislative
- an FDA center of excellence for healthspan products
- application of accelerated approval to therapies targeting age-related diseases and multimorbidity

legislative
- Multi-Disease Therapeutic Designation to enable cross-division communication with FDA for multimorbidity registrational plans
- THRIVE Act tiered-approval approach for healthspan products

[The Alliance for Longevity Initiatives (A4LI) @theA4LI]

Russia has committed $26 billion to longevity science, while China is advancing large-scale stem cell anti-aging trials and expanding aggressive investment in regenerative medicine and longevity biotechnology.

Scientific leadership in longevity is rapidly becoming a defining frontier of global competitiveness. The United States cannot afford to sit on the sidelines.

Join our letter campaign: https://t.co/1OJsue0fkD

[Ultrahuman @UltrahumanHQ]

https://t.co/usi05FRRjA

[STAT @statnews]

Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday. https://t.co/t5FPSkow1D

[José Luis Ricón Fernández de la Puente @ArtirKel]

We raised $$!
https://t.co/G5Y3eXoytx

[ben ray @_benray]

“The logical thing to do is to use conventional equipment in an unconventional way to get to scale, and then start modifying the equipment to increase the rate”

[Alex Trapp @AlexandreTrapp]

@andrewpannu @MichaelRetchin Sleuth

[Samuel Hume @DrSamuelBHume]

Charts of the week

https://t.co/rSht7wnAEZ